Clinical-stage biotech OphthaliX files for a $10 million IPO

OphthaliX, a clinical-stage biotech developing treatments for ophthalmic disorders, filed on Tuesday with the SEC to raise up to $10 million in an initial public offering. The Petach Tikva, Israel-based company, which was founded in 1999, plans to list on the NYSE but has yet to announce a ticker. Maxim Group is the sole bookrunner on the deal. No pricing terms were disclosed.